SEPN Stock Overview
A clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Septerna, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.17 |
| 52 Week High | US$28.99 |
| 52 Week Low | US$11.78 |
| Beta | 0 |
| 1 Month Change | -26.79% |
| 3 Month Change | -44.15% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -38.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| SEPN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -15.6% | 0.6% | 1.2% |
| 1Y | n/a | 0.5% | 21.0% |
Return vs Industry: Insufficient data to determine how SEPN performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SEPN performed against the US Market.
Price Volatility
| SEPN volatility | |
|---|---|
| SEPN Average Weekly Movement | 12.6% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 18.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SEPN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SEPN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 73 | Jeff Finer | septerna.com |
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves’ disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes.
Septerna, Inc. Fundamentals Summary
| SEPN fundamental statistics | |
|---|---|
| Market cap | US$581.23m |
| Earnings (TTM) | -US$19.85m |
| Revenue (TTM) | US$981.00k |
596.1x
P/S Ratio-29.5x
P/E RatioIs SEPN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SEPN income statement (TTM) | |
|---|---|
| Revenue | US$981.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$981.00k |
| Other Expenses | US$20.83m |
| Earnings | -US$19.85m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,023.34% |
| Debt/Equity Ratio | 0% |
How did SEPN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/10 06:50 |
| End of Day Share Price | 2025/02/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Septerna, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Eric Joseph | J.P. Morgan |
| Yaron Werber | TD Cowen |